To evaluate the uric acid lowering efficacy of Febuxostat in patients with chronic renal failure stage III

The present study was done to evaluate the uric acid lowering efficacy of Febuxostat in patients with chronic renal failure stage III. A single centered open label study was conducted in 30 patients for 4 weeks. Tablet Febuxostat 40 mg once daily resulted in significant serum uric acid reductions. Liver function and estimated glomerular filtration rate (eGFR) were not significantly altered. Febuxostat is safe potent hypouricemic drug in patients with moderate renal impairment.